Introduction
This report summarizes the case studies presented and ensuing discussions held during Track 6 of the DIA-FDA-PWG-PhRMA-BIO Pharmacogenomic Workshop on 'Retrospective Validation of Genomic Biomarkers -What are the Questions, Challenges and Strategies for Developing Useful Relationships to Clinical Outcomes' held in Washington, DC in April 2005. Because pharmacogenomics depends largely on the patients' genetic background, it seems likely that there will be variations across populations in patterns and markers that predict a particular drug's side-effect risk and efficacy. In addition, the genetic basis or contribution to disease may vary across populations and make prediction of response and efficacy nonuniform, so that what is true for one group will be either not true, or only partially true, for another group. The regulatory landscape upon which pharmacogenomics is being developed is also non-uniform and has the potential to confound drug development for a global market. The goal of this session was to explore international regulatory issues related to the development of drugs and, when warranted, their accompanying diagnostics and to identify some areas where harmonization may be possible. Along with the authors of this paper, these individuals comprised the panel: Eric Abadie (EMEA), Lawrence J. Lesko, (CDER, FDA), Marisa Papaluca (EMEA), Yoshiaki Uyama (PMDA, Japan), Sanae Yasuda (Eisai Co., Ltd), and Christopher Webster (Millennium Pharmaceuticals, Inc.).
Case studies and workshop discussion
Case study no.1: To test or not to test? This example served to elicit discussion around two central points: (1) efficacy versus safety biomarkers and (2) international viewpoints on combined drug/diagnostic products.
Case study description. A new drug in a novel pharmaceutical class is being developed for a serious disease. The sponsors of the drug have determined that a test can be developed to predict which patients will benefit therapeutically from the drug and which will not. The sponsors have also determined that some patients may be at a risk for a serious adverse effect and a separate test can be developed which will identify at risk patients. The panel was asked the following key questions: However, if the population genetics regarded the target and how its genetic variations affect efficacy, it was thought that there could be some instances where another trial would not be needed. For example, if the sponsor has extensive knowledge of mechanistic and target behavior about the drug, so that efficacy could be confidently predicted for the Japanese population, this information could influence whether another trial would be requested. However, this scenario is currently considered unlikely.
Environment is of course one of the notable confounding variables known to exist between Japanese and Western populations. Therefore, the Japanese agency is concerned that pharmacogenomic studies supporting drug applications in Japan account for major environmental variables, such as prevalence of smokers, and prior drug exposure. In order to accomplish this in the most efficient manner, a bridging trial using Japanese patients in Japan might be adequate for regulatory purposes, and would be encouraged as a minimum consideration by the MHLW.
As ideally all parties would like to achieve drug approval without unwarranted expenditure in time and resources, the question of what is 'nice to know' and what is mandated for drug approval by the various regulatory agencies was examined. The answer, common to all the regulatory agencies represented, was unsurprising -this is always predicated on risk/ benefit ratio of the drug/test combination in the represented population, what disease or class of disease or condition is being considered, and whether other treatment options exist that may have fewer risks or greater benefits than the drug/test in question.
In conclusion, the three major regulatory agencies represented in case study 2 agreed that there could be genetic differences among specific populations that would necessitate additional studies, and that this should be based on scientific principles of what is known and not known. All agencies felt that pharmacogenomics could benefit drug development, and possibly drug administration, although exact requirements could not be given for how it should be used in the drug approval process in Japan.
Case study no. 3: Regulatory engagement timetable This case was developed to explore the timing of regulatory interactions by the sponsor, to identify the type of information required for such a meeting and whether a pharmacogenomic assay could be used to set the doses to be tested in humans. In typical doseresponse studies, doses are based upon the maximum tolerated dose (MTD) to maximize efficacy. However, with newer targeted therapies, this may not reveal an appropriate dose and one may need new biomarkers to set efficacy doses.
Case study description. A company wants to use genetic biomarkers to evaluate the pharmacologic response (e.g. dose-response relationships) to set clinical dose levels and duration of treatment for an experimental oncology compound. The panel was asked the following key questions:
1. At what point during the drug development process should the company approach the regulatory authorities for informal consultation and format guidance? 2. Would there be a way to have early meetings (e.g. type 2A meeting proposed by FDA) with regulatory agencies to discuss existing doseresponse relationship data to select the appropriate dose?
3. How much data (non-clinical, clinical, validation) would the company need to put forward as a rationale for this approach? Could non-GLP data be used in support? 4. Would a dose ranging study increasing the dose to the MTD still be required if the dose to be used in efficacy trials would be substantially lower based upon use of a biomarker? 5. How would access and approach to the regulatory authorities differ if the biomarker were to be used to limit the dose of an approved product in certain patients to avoid a serious dose-related toxicity, for example, cardiac toxicity?
Discussion. The panel felt that the familiarity of the biomarker (i.e. wellknown versus novel) would drive the timing of the meetings; a novel biomarker would warrant an earlier meeting. In any case, the meeting should be held when the dose selection is being made and non-GLP data was acceptable in support of such an application. As to proactive sample collection and location of analyses of such, it was stated that Japanese regulators actively encourage sponsors to collect samples for potential pharmacogenomic studies and felt that such samples could be assayed in other countries. All agreed that it would be best to share data among international regulators as they need to establish a strong global framework. However, caution was raised on several issues.
(1) All should be aware of country-specific legal issues faced by regulatory agencies on the sharing of proprietary information. (2) It was unclear how a company would consolidate information from these meetings particularly if each agency reached its own conclusions. The panel felt that if a sponsor is approaching an agency for an early meeting, it would tend to be more informal. However, it was stressed that even this type of meeting would require preparation on both sides and the sponsor should be prepared to present relevant data such as any results that would illustrate dose--response and preclinical species correlation. In some cases regulators may want the sponsor to use diseasestate models to understand the mechanism of disease and drug targets. The FDA is storing such information with drug class and can share overall experience but, of course, cannot share proprietary information. As with their US counterparts, European regulators are looking at new technologies and requested that a sponsor offer sufficient details on their methodology prior to the meeting so that the agency could assess whether external experts should be invited to the meeting to serve as agency consultants. The scenario was posed in which a genetic biomarker is discovered that could limit doses to avoid toxicity caused by a product after it has been approved. What would be the implications from a regulatory viewpoint? In Europe one could add this to the label if use of this biomarker is the only way to avoid toxicity (i.e. a highly definitive discriminator), makes good clinical practice and fits the regulatory environment. The Japanese regulatory agency would need to review the new data to determine if the biomarker's reliability was sufficient to warrant a change in the label. The FDA normally thinks of surrogates in terms of efficacy and not toxicity and noted that because of the limited size of clinical trials, it may be difficult to validate a safety biomarker post marketing.
Case study no. 4: Retrospective signals
This case involves a drug that would be approved under current regulations as it met its efficacy goals although only at a minimal level. How would use of a biomarker affect the approval of this drug? An important consideration is whether retrospective analysis of samples could be utilized as this situation is likely to be commonplace in the drug development cycle wherein advanced knowledge of biomarkers may be difficult to obtain.
Case study description. A Phase 2 study in depression indicated that the drug under investigation would (only) satisfy minimum efficacy criteria to continue the development program; however, close examination of these results reveal an unexpected variability in treatment response between individuals. Blood samples had been collected and stored in an appropriate manner during this study. Pharmacogenetic analyses were performed retrospectively and a number of candidate genes investigated to determine their relationship to disease pathophysiology and to the compound's metabolic pathway and its pharmacological action. A preliminary pharmacogenetic marker set was identified that correlated with efficacy and was shown to be 'predictive' for a subgroup of patients with particularly good treatment response; these biomarkers would enable the selection of patients for the planned Phase 2b and 3 studies. The following issues were addressed:
1. Would pharmacogenetic analysis be a prerequisite for progression to Phase 2b/3? 2. What dose response data in the genotype groups might be required? 3. Would testing of patients for the efficacy markers be mandatory prior to prescribing? 4. Would regulators request that pharmacogenetic testing be conducted on existing compounds (in development or on the market) of the same pharmacologic class?
Discussion. At this stage, and as the minimal criteria for efficacy in the general test population was fulfilled, there would be no requirement by regulatory authorities to use pharmacogenetic testing in further clinical studies. It would, however, be important to understand the pharmacogenetic basis of differences in treatment response and, if differences would be related to, for example, a CYP2D6 polymorphism and potential higher plasma levels in treatment responders. Conclusions potentially could be drawn for a differential dosing regimen in intermediate and fast metabolizers. If the sponsor proposes to limit the development program to 'responders' this would be acceptable provided that treatment response shows a relevant difference between groups and the pharmacogenetic prediction of treatment response were sufficiently reliable and confirmed in Phase 2b/3. Dose-response testing in one or both of the subgroups identified by the preliminary set of candidate genes predictive for response would be a case-by-case decision and, again, depend on the plausibility of the pharmacogenetic test with regard to, for example, drug metabolism or mechanism of action. Of course, if the development of the drug were focused on likely treatment responders, the prescription of the marketed drug would have to rely on the development/ availability of the pharmacogenetic test as well. As the test is incorporated in further development steps early on (before Phase 2b) regulators would expect validation of the pharmacogenetic marker panel and a submission for approval parallel to the drug approval process.
Workshop summary
The use of pharmacogenomics in drug development is posing novel issues particularly in today's global marketplace wherein genetic differences exist among diverse populations. This workshop served as a starting point in the discussion of how regulators in various countries will deal with these new advances. The overall goal was to obtain an initial understanding of barriers, burdens and benefits to the use of pharmacogenomics and the value of standardization among diverse global regions from the industry and the regulatory authorities' point of view. It was agreed that a good place to begin is a harmonization around the coding samples containing DNA in a manner that meets patient privacy concerns.
Although pharmacogenomic biomarkers may not be recognized until relatively late in development, all still felt that retrospective analysis of patient samples collected during clinical trials would be insufficient to validate fully such biomarkers. In addition, unless it can be proven that genetic diversity is similar among the global populations, additional studies may be required for drug approval in Japan, for example, with their relative homogenous patient population. There are a few success stories of the co-development of devices with drugs (e.g. Herceptin) with likely more coming in the future as new biomarkers are discovered and qualified. Although all regulatory agencies felt that pharmacogenomics could benefit drug development, as was expected, this workshop illustrated some differences in their approaches. The panel felt it was important to develop global cohesive regulatory strategies in this developing area and this is one topic of the International Conference on Harmonization that will be held in November 2005. This is a suitable place for harmonization as their guidelines are binding. As pharmacogenomics is currently an evolving technology, its role in drug development will be decided on a case-by-case basis, even within one agency, and factors such as risk/ benefit ratio, disease indication, etc. will need to be taken into account. Regulators strongly encouraged sponsors to discuss the pharmacogenomic aspects of a drug's development early in the process so that mutually agreeable study designs can be put into place that will enable their drugs to move forward toward approval and the goal of improving patient's therapeutic response.
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